Teos (ITOS) stock is in focus as experimental cancer doublet therapy, developed with GSK, outperformed Jemperliin a mid-stage ...

High response rates reported by GSK and iTeos at the 2024 European Society for Medical Oncology Congress offer a ray of light ...

Results presented at ESMO showed tumor response rates that matched the bar set by analysts for success. But they may not yet ...

Teos Therapeutics' belrestotug shows promising response rates in lung cancer trials. Read more to see why I'm bullish on ITOS ...

The results of the GALAXIES Lung-02 study reported at the ESMO congress in Barcelona showed that the drug – added to GSK's PD ...

iTeos Therapeutics shares dipped 13.7% to $14.40 in pre-market trading. Here are some big stocks recording losses in today's ...

Shares in iTeos Therapeutics dropped over 20% despite positive interim data from the GALAXIES Lung-201 Phase II study with ...

The published belrestotug/dostarlimab data is still too immature to prove the combination’s capability to disrupt the NSCLC ...

Shares in iTeos Therapeutics rose after the company reported positive data from a mid-stage study exploring the combination of belrestotug and dostarlimab in the first-line treatment of lung cancer.

Swayampakula Ramakanth, an analyst from H.C. Wainwright, maintained the Buy rating on iTeos Therapeutics (ITOS – Research Report). The ...

Piper Sandler analyst Christopher Raymond maintained a Buy rating on iTeos Therapeutics (ITOS – Research Report) today and set a price ...

Check the time stamp on this data. Updated AI-Generated Signals for Iteos Therapeutics Inc. (ITOS) available here: ITOS.